Immunocore Q4 Earnings Call Highlights [Yahoo! Finance]
Immunocore Holdings plc - American Depositary Shares (IMCR)
Company Research
Source: Yahoo! Finance
Immunocore reported KIMMTRAK net revenue of $400 million in 2025, up more than 29% year-over-year, with launches in 30 markets and approvals in 39 countries; commercial momentum includes a 15th consecutive quarter of growth, 70% penetration in major markets and 70% of prescriptions coming from the community setting, with real-world mean therapy duration of 14 months and a median overall survival of 28 months in a 150-patient dataset. Management expects KIMMTRAK growth to moderate as the product enters its fifth year, citing recent sequential quarterly growth of 4%–7% and an underlying normalized year-over-year growth rate of around after rebate adjustments, with slower growth anticipated in 2026. The late-stage pipeline includes three phase III melanoma trials— TEBE-AM (possible registrational readout H2 2026), ATOM (U.S. site activations H1 2026) and PRISM-MEL (enrollment targeted for 2027)—while PRAME programs, HIV/hepatitis B efforts and autoimmunity candidates advance; the co
Show less
Read more
Impact Snapshot
Event Time:
IMCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMCR alerts
High impacting Immunocore Holdings plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
IMCR
News
- Immunocore to present at upcoming investor conferencesGlobeNewswire
- Is It Time To Revisit Immunocore Holdings (IMCR) After Recent Pipeline Progress? [Yahoo! Finance]Yahoo! Finance
- Immunocore (IMCR) was downgraded by Zacks Research from "strong-buy" to "hold".MarketBeat
- Immunocore (IMCR) had its price target raised by Needham & Company LLC from $71.00 to $75.00. They now have a "buy" rating on the stock.MarketBeat
- Immunocore Holdings PLC (IMCR) Q4 2025 Earnings Call Highlights: Robust Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
IMCR
Earnings
- 2/25/26 - Miss
IMCR
Sec Filings
- 2/25/26 - Form 8-K
- 2/25/26 - Form 10-K
- 2/19/26 - Form 4
- IMCR's page on the SEC website